Richter Gedeon Nyrt.

Gruenenthal Gmbh

Grunenthal Gmbh

Georg Schramm

Johannes Bartholomäus

Johannes Schneider

Eric-Paul Paques

Christa Kneip

Klaus-Michael Wilsmann

Rainer Henske

Janine Klose

Karl-Heinz Oedekoven

Eric-Paul Pâques

The present invention relates to a medicament in the form of daily units, which contain an active ingredient combination consisting of a hormone combination with contraceptive action consisting of at least one oestrogen selected from the group consisting of estradiol and ethinyl estradiol and at least one gestagen selected from the group consisting of chlormadinone acetate, 3-&#x3b2;-OH-chlormadinone acetate, 3-&#x3b1;-OH-chlormadinone acetate, 3-&#x3b1;-acetoxy-chlormadinone acetate and 3-&#x3b2;-acetoxy-chlormadinone acetate, and at least one insulin sensitiser and which are combined to provide a dosage form with daily units which only contain an insulin sensitiser as the sole active ingredient, and to the use of this dosage form for preventing or treating pathological disorders caused by polycystic ovary syndrome (PCOS) and for simultaneous contraception.

Pharmaceutical containing a hormone combination having a contraceptive effect and an insulin sensitizer

The present invention relates to a hormonal contraceptive including 21 to 25 hormone-containing daily units, which contain a combination of ethinyloestradiol in an amount of &#x2267;25 &#x3bc;g and chlormadinone acetate in an amount of &#x2267;5 mg, and optionally 7 to 3 hormone-free daily units for oral administration to women.

Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate

The present invention relates to a hormonal contraceptive including at least 120 hormone-containing daily units, which contain 5 to 50 &#x3bc;g of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate, and optionally 7 to 3 hormone-free daily units for uninterrupted oral administration to women.

A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.

Dosage form for hormonal contraception

The present invention relates to the use of 3&#x3b2;-hydroxychlormadinone acetate (17&#x3b1;-acetoxychloropregna-4,6-dien-3&#x3b2;-ol-20-one) and/or 3&#x3b1;-hydroxychlormadinone acetate (17&#x3b1;-acetoxychloropregna-4,6-dien-3&#x3b1;-ol-20-one) for producing a medicament for treating skin, preferably human skin by means of topical application, and to a pharmaceutical or cosmetic composition containing 3&#x3b2;-hydroxychlormadinone acetate and/or 3&#x3b1;-hydroxychlormadinone acetate.

3-hydroxychlormadinone acetate for the topical treatment of androgen-dependent skin diseases

The present invention relates to the use of at least one gestagen selected from the group consisting of chlormadinone acetate, 3&#x3b1;-hydroxy-6-chloro-17&#x3b1;-acetoxy-4,6-pregnadien-20-one (3&#x3b1;-hydroxy-chlormadinone acetate) and 3&#x3b2;-hydroxy-6-chloro-17&#x3b1;-acetoxy-4,6-pregnadien-20-one (3&#x3b2;-hydroxy-chlormadinone acetate) as gestagen component and optionally at least one oestrogen selected from the group consisting of ethinyl oestradiol, oestrone, oestriol as oestrogen component and oestradiol to produce a medicament for the treatment and/or prevention of melasma and optionally for simultaneous hormonal contraception or optionally for simultaneous hormone replacement for women.

Drug comprising at least one gestagen

A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain at most 200 &#x3bc;g of folic acid and the daily units B contain &#x3e;200 &#x3bc;g up to the maximum permissible amount of folic acid for women.

The present invention relates to a medicament which contains as the active ingredient combination at least one gestagen with a contraceptive action as the sole hormone component and at least one insulin sensitizer, which medicament is in particular suitable for preventing or treating pathological disorders which are caused by polycystic ovary syndrome (PCOS).

Growing community of inventors

Stolberg, Germany

Georg Schramm